Seattle Genetics (SGEN) Receives a Buy from H.C. Wainwright
In a report released today, Andrew Fein from H.C. Wainwright maintained a Buy rating on Seattle Genetics (SGEN), with a price target of $140.00. The company’s shares closed last Monday at $100.89, close to its 52-week high of $102.84.
According to TipRanks.com, Fein is a 1-star analyst with an average return of -1.2% and a 37.3% success rate. Fein covers the Healthcare sector, focusing on stocks such as Constellation Pharmaceuticals Inc, DBV Technologies SA – American, and Proteostasis Therapeutics Inc.
The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Seattle Genetics with a $95.00 average price target, implying a -1.6% downside from current levels. In a report released yesterday, Needham also maintained a Buy rating on the stock with a $121.00 price target.
See today’s analyst top recommended stocks >>
The company has a one-year high of $102.84 and a one-year low of $50.71. Currently, Seattle Genetics has an average volume of 978.1K.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Seattle Genetics, Inc. is a biotechnology company, which engages in the development and commercialization of antibody-based therapies for the treatment of cancer. Its product Adcetris is an antibody-drug for the treatment of lymphoma. The firm is also advancing a pipeline of novel therapies for solid tumors and blood-related cancers.
Read More on SGEN: